FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1326-1327 April 26, 2001 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Anxiety disorders represent the most common group of serious psychiatric conditions affecting children and adolescents. In a community-based study, approximately 3 percent of 9-to-17-year-olds had a diagnosable anxiety disorder that caused serious impairment.¹ Yet, there is little information from rigorously controlled studies on the efficacy of the pharmacologic treatment of these disorders. Thus, the report by the Research Unit on Pediatric Psychopharmacology Anxiety Study Group² in this issue of the Journal provides a much-needed examination of the topic.

The study group evaluated the efficacy of fluvoxamine, a selective serotonin-reuptake inhibitor, in boys and girls who were 6 to 17 years . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.